PCVX Q3 2021 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$8B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$27M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$30M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$354M

Total Liabilities

$48M

Stockholders' Equity

$306M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$27M	-$21M	-26.5%
Net Income	-$27M	-$21M	-26.6%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%